PDA

View Full Version : Eisai is appalled by arbitrary decision to remove life-extending breast cancer therap

News
01-09-2015, 04:20 AM
Eisai has announced its extreme disappointment that the National Cancer Drugs Fund(NCDF) panel has apparently made the decision to remove Halaven(R) (eribulin) from theCancer Drugs Fund (CDF)...

More... (http://www.medicalnewstoday.com/releases/287801.php)